Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00692939 · ClinicalTrials.gov registry record · Phase 1
Autologous Stem Cell Transplantation for Crohn's Disease
A Phase 1 study of Crohn's Disease, sponsored by Paul Szabolcs.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 20
- Enrollment target
- 2
- Study locations
NCT00692939: Recruiting Phase 1 study of Crohn's Disease, sponsored by Paul Szabolcs.
NCT00692939 is a Phase 1 study of Crohn's Disease that is actively recruiting participants, run by Paul Szabolcs. The registered enrollment target is 20 participants, below the 2,394-participant average among 105 other Crohn's Disease trials with a reported enrollment target (99% lower). The trial reports 2 study locations across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00692939, a Phase 1 study of Crohn's Disease, is actively recruiting participants, sponsored by Paul Szabolcs.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 20 participants
- Enrollment target
- 2
- Study locations
Study Summary
The objective of this study is to evaluate the safety and effectiveness of administering high-dose chemotherapy followed by infusion of autologous CD34-selected peripheral blood stem cells (PBSC) in pediatric and adult patients with severe Crohn's disease.
Conditions Studied
Interventions
- DRUG Melphalan
- DRUG Alemtuzumab
- DRUG Thiotepa
- BIOLOGICAL autologous CD34-selected peripheral blood stem cells transplant
- DRUG ATG
Study Locations (2)
Pennsylvania
- UPMC Prebyterian- Adult Gastroenterology - Pittsburgh
- Children's Hospital of Pittsburgh of UPMC-Bone Marrow Team - Pittsburgh
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 20 participants |
| Start Date | 2012-06-26 |
| Est. Completion | 2027-12 |
| Phase | Phase 1 |
What NCT00692939 shows while recruiting
NCT00692939 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 20 participants, a relatively small participant target, below the 2,394-participant average among 105 other Crohn's Disease trials with a reported enrollment target (99% lower).
The record links to 1 condition, with Crohn's Disease appearing as the primary indexed condition, and to 5 interventions - of which Melphalan is the first listed.
NCT00692939 reports a single indexed study location in Pennsylvania.
Frequently Asked Questions
What is clinical trial NCT00692939 about?
NCT00692939 is a clinical study titled "Autologous Stem Cell Transplantation for Crohn's Disease". The objective of this study is to evaluate the safety and effectiveness of administering high-dose chemotherapy followed by infusion of autologous CD34-selected peripheral blood stem cells (PBSC) in pediatric and adult patients with severe Crohn's disease.
What is the current status of trial NCT00692939?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 20 participants. The study started on 2012-06-26. Estimated completion is 2027-12.
What conditions does trial NCT00692939 study?
This clinical trial studies the following conditions: Crohn's Disease.
What interventions are being tested in trial NCT00692939?
The interventions under investigation include: Melphalan (DRUG), Alemtuzumab (DRUG), Thiotepa (DRUG), autologous CD34-selected peripheral blood stem cells transplant (BIOLOGICAL), ATG (DRUG).
Who is sponsoring clinical trial NCT00692939?
This trial is sponsored by Paul Szabolcs, which has 7 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00692939 being conducted?
This trial has 2 study locations across Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Crohn's Disease
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00692939's enrollment target sits among peer trials
20 99th of 105 higher than 6 of 105 other Crohn's Disease trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Crohn's Disease trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
An Open-Label, Proof of Consent Study of Vorinostat for the Treatment of Mdoerate-to-Severe Crohn s Disease and Maintenance Therapy With Ustekinumab
RECRUITING · Phase 1
-
Beta-Hydroxybutyrate Feasibility Treating IBD
RECRUITING · Phase 1
-
Treatment of Moderate to Severe Refractory Crohn's Disease
RECRUITING · Phase 1
-
Study to Evaluate Safety, Tolerability and Efficacy of Oral E-B-FAHF-2 in Mild-to-Moderate Crohn's Disease
ACTIVE NOT RECRUITING · Phase 1
-
Use of Oral Probiotics to Reduce Urinary Oxalate Excretion
COMPLETED · Phase 1
-
Single Ascending Dose Study of Oral CPSI-2364 (Semapimod)
COMPLETED · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00573339 · 20 participants
Cardiac Magnetic Resonance Imaging (MRI) Normal Reference Control Group Testing
- NCT00967785 · 20 participants · Phase 1
A Phase I Study of Mozobil in the Treatment of Patients With WHIMS
- NCT01406691 · 20 participants · Phase 4
Light Flashes to Treat Delayed Sleep Phase Disorder (DSPD)
- NCT01630850 · 20 participants · NA
Islet Transplantation in Patients With "Brittle" Type I Diabetes
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI